256 related articles for article (PubMed ID: 28476872)
1. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Skinner HD; Giri U; Yang LP; Kumar M; Liu Y; Story MD; Pickering CR; Byers LA; Williams MD; Wang J; Shen L; Yoo SY; Fan YH; Molkentine DP; Beadle BM; Meyn RE; Myers JN; Heymach JV
Clin Cancer Res; 2017 Jun; 23(11):2713-2722. PubMed ID: 28476872
[No Abstract] [Full Text] [Related]
2. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
McDaniel NK; Iida M; Nickel KP; Longhurst CA; Fischbach SR; Rodems TS; Kranjac CA; Bo AY; Luo Q; Gallagher MM; Welke NB; Mitchell KR; Schulz AE; Eckers JC; Hu R; Salgia R; Hong S; Bruce JY; Kimple RJ; Wheeler DL
Clin Cancer Res; 2020 Aug; 26(16):4349-4359. PubMed ID: 32439698
[TBL] [Abstract][Full Text] [Related]
3. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
4. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL
Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293
[TBL] [Abstract][Full Text] [Related]
5. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
[TBL] [Abstract][Full Text] [Related]
6. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Fiedler M; Schulz D; Piendl G; Brockhoff G; Eichberger J; Menevse AN; Beckhove P; Hautmann M; Reichert TE; Ettl T; Bauer RJ
Exp Cell Res; 2020 Nov; 396(1):112259. PubMed ID: 32898555
[TBL] [Abstract][Full Text] [Related]
7. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
Front Immunol; 2019; 10():1644. PubMed ID: 31379843
[No Abstract] [Full Text] [Related]
8. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
9. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
10. AXL mediates resistance to cetuximab therapy.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL
Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066
[TBL] [Abstract][Full Text] [Related]
11. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
12. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer.
Skinner HD; Giri U; Yang L; Woo SH; Story MD; Pickering CR; Byers LA; Williams MD; El-Naggar A; Wang J; Diao L; Shen L; Fan YH; Molkentine DP; Beadle BM; Meyn RE; Myers JN; Heymach JV
Clin Cancer Res; 2016 Sep; 22(18):4643-50. PubMed ID: 27036135
[TBL] [Abstract][Full Text] [Related]
13. Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.
Bates AM; Lanzel EA; Qian F; Abbasi T; Vali S; Brogden KA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Aug; 124(2):157-164. PubMed ID: 28756882
[TBL] [Abstract][Full Text] [Related]
14. Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Schulz D; Streller M; Piendl G; Brockhoff G; Reichert TE; Menevse AN; Beckhove P; Hautmann MG; Bauer RJ; Ettl T
Carcinogenesis; 2020 Jul; 41(7):984-992. PubMed ID: 31637423
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
17. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495
[TBL] [Abstract][Full Text] [Related]
18. Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
Fiedler M; Weber F; Hautmann MG; Haubner F; Reichert TE; Klingelhöffer C; Schreml S; Meier JK; Hartmann A; Ettl T
Clin Oral Investig; 2018 Jan; 22(1):189-200. PubMed ID: 28315964
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
20. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Elkabets M; Pazarentzos E; Juric D; Sheng Q; Pelossof RA; Brook S; Benzaken AO; Rodon J; Morse N; Yan JJ; Liu M; Das R; Chen Y; Tam A; Wang H; Liang J; Gurski JM; Kerr DA; Rosell R; Teixidó C; Huang A; Ghossein RA; Rosen N; Bivona TG; Scaltriti M; Baselga J
Cancer Cell; 2015 Apr; 27(4):533-46. PubMed ID: 25873175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
